Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab

BACKGROUND: Immune checkpoint inhibitors (ICIs) are currently the standard therapy in advanced non-small cell lung cancer (NSCLC); however, there is no well-established prognostic biomarker. We investigated the relationship between survival outcomes and three peripheral blood biomarkers, including t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Gastaldo, Amparo, Muñoz-Fuentes, Miguel A., Molina-Pinelo, Sonia, Alonso-García, Miriam, Boyero, Laura, Bernabé-Caro, Reyes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264316/
https://www.ncbi.nlm.nih.gov/pubmed/34295658
http://dx.doi.org/10.21037/tlcr-21-156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264316/
https://www.ncbi.nlm.nih.gov/pubmed/34295658
http://dx.doi.org/10.21037/tlcr-21-156

Ejemplares similares